Blueprint Medicines Corp BPMC:NASDAQ

Last Price$94.25NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$94.26 (2)
Ask (Size)$122.22 (4)
Day Low / HighN/A - N/A
Volume614.5 K
 

View Biotechnology IndustryPeer Comparison as of 12/03/2021

 

Blueprint Medicines Corp ( NASDAQ )

Price: $94.25
Change: -4.26 (4.32%)
Volume: 614.5 K
4:00PM ET 12/03/2021
 
 

Denali Therapeutics Inc ( NASDAQ )

Price: $42.59
Change: -1.92 (4.31%)
Volume: 884.7 K
4:00PM ET 12/03/2021
 
 

Ultragenyx Pharmaceutical Inc ( NASDAQ )

Price: $76.01
Change: -3.11 (3.93%)
Volume: 822.7 K
4:00PM ET 12/03/2021
 
 

Exelixis Inc ( NASDAQ )

Price: $15.84
Change: -0.64 (3.88%)
Volume: 2.5 M
4:00PM ET 12/03/2021
 
 

Fate Therapeutics Inc ( NASDAQ )

Price: $48.00
Change: -4.60 (8.75%)
Volume: 1.2 M
4:00PM ET 12/03/2021
 

Read more news Recent News

Wedbush Adjusts Blueprint Medicines PT to $139 From $136, Maintains Outperform Rating
12:34PM ET 11/29/2021 MT Newswires

Blueprint Medicines (BPMC) has an average rating of Outperform and price targets ranging from $84 to $152, according to analysts polled by Capital IQ. (MT...

Blueprint Medicines to Acquire Lengo Therapeutics
7:23AM ET 11/29/2021 MT Newswires

Blueprint Medicines (BPMC) said Monday it has agreed to acquire Lengo Therapeutics for $250 million in cash plus up to $215 million in milestone payments. ...

Insider Sell: Blueprint Medicines
5:33PM ET 11/17/2021 MT Newswires

Jeffrey W. Albers, Director, CEO and President, on November 15, 2021, sold 30,000 shares in Blueprint Medicines (BPMC) for $3,435,099. Following the Form 4...

--Raymond James Adjusts Blueprint Medicines' Price Target to $133 From $122, Keeps Strong Buy Rating
6:47AM ET 11/10/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
7:24AM ET 12/03/2021 Zacks

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and...

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
7:24AM ET 12/03/2021 Zacks

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and...

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
7:24AM ET 12/03/2021 Zacks

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and...

IDNA: Healthcare Dashboard For November
4:12AM ET 11/19/2021 Seeking Alpha

Company Profile

Business DescriptionBlueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA. View company web site for more details
Address45 Sidney Street
Cambridge, Massachusetts 02139
Phone+1.617.374.7580
Number of Employees217
Recent SEC Filing11/29/20218-K
President, Chief Executive Officer & DirectorJeffrey W. Albers
Chief Operating OfficerKathryn Haviland
Chief Financial OfficerMichael Landsittel
Chief Medical OfficerBecker Hewes

Company Highlights

Price Open$98.86
Previous Close$98.51
52 Week Range$79.08 - 125.61
Market Capitalization$5.5 B
Shares Outstanding58.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/16/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$7.10
Beta vs. S&P 500N/A
Revenue$44.5 M
Net Profit Margin-383.58%
Return on Equity-30.19%

Analyst Ratings as of 09/28/2021

Buy
9
Overweight
1
Hold
5
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset